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Summary
Background Measuring a country’s health performance has focused mostly on estimating levels of mortality. 
An alternative is to measure rates of decline in mortality, which are more sensitive to changes in health policy than 
are mortality levels. Historical rates of decline in mortality can also help test the feasibility of future health goals 
(eg, post-2015). We aimed to assess the annual rates of decline in under-5, maternal, tuberculosis, and HIV mortality 
over the past two decades for 109 low-income and middle-income countries.
Methods For the period 1990–2013, we estimated annual rates of decline in under-5 mortality (deaths per 
1000 livebirths), the maternal mortality ratio (deaths per 100 000 livebirths), and tuberculosis and HIV mortality 
(deaths per 100 000 population per year) using published data from UNICEF and WHO. For every 5-year interval 
(eg, 1990–95), we deﬁ ned performance as the size of the annual rate of decline for every mortality indicator. 
Subsequently, we tested the feasibility of post-2015 goals by estimating the year by which countries would achieve 
2030 targets proposed by The Lancet’s Commission on Investing in Health (ie, 20 deaths per 1000 for under-5 
mortality, 94 deaths per 100 000 for maternal mortality, four deaths per 100 000 for tuberculosis mortality, and eight 
deaths per 100 000 for HIV mortality) at observed country and aspirational best-performer (90th percentile) rates.
Findings From 2005 to 2013, the mean annual rate of decline in under-5 mortality was 4·3% (95% uncertainty interval 
[UI] 3·9–4·6), for maternal mortality it was 3·3% (2·5–4·1), for tuberculosis mortality 4·1% (2·8–5·4), and for HIV 
mortality 2·2% (0·1–4·3); aspirational best-performer rates per year were 7·1% (6·8–7·5), 6·3% (5·5–7·1), 12·8% 
(11·5–14·1), and 15·3% (13·2–17·4), respectively. The top two country performers were Macedonia and South Africa 
for under-5 mortality, Belarus and Bulgaria for maternal mortality, Uzbekistan and Macedonia for tuberculosis 
mortality, and Namibia and Rwanda for HIV mortality. At aspirational rates of decline, The Lancet’s Commission on 
Investing in Health target for under-5 mortality would be achieved by 50–64% of countries, 35–41% of countries 
would achieve the 2030 target for maternal mortality, 74–90% of countries would meet the goal for tuberculosis 
mortality, and 66–82% of countries would achieve the target for HIV mortality.
Interpretation Historical rates of decline can help deﬁ ne realistic targets for Sustainable Development Goals. The gap 
between targets and projected achievement based on recent trends suggests that countries and the international 
community must seek further acceleration of progress in mortality.
Funding Bill & Melinda Gates Foundation, NORAD.
Copyright © Verguet et al. Open Access article distributed under the terms of CC BY-NC-SA.
Introduction
Assessing a country’s health performance is diﬃ  cult. 
Across and within countries, policies can aﬀ ect 
population health directly or indirectly and might vary 
substantially in scope and delivery. This diversity and 
complexity challenges our understanding of the systemic 
causes of success or failure and, ultimately, limits cross-
country comparability.1
A country’s performance in health is typically deﬁ ned 
by how much better or worse it is faring with respect to a 
selected outcome (eg, life expectancy) compared with 
what would be expected in view of selected contextual 
attributes (eg, income and education).2 In the Good 
Health at Low Cost study,3 an attempt was made to assess 
country performances in levels of mortality; a case-study 
approach was used to examine why three countries and 
one Indian state had low mortality levels despite scant 
resources. Later analyses also quantiﬁ ed performance 
with respect to levels of mortality and fertility.4
Numbers of deaths are aﬀ ected strongly by 
longstanding country-level determinants. Essentially, a 
country that starts with a low level of mortality is likely to 
persist with fewer deaths, whereas a country that begins 
at a high level might improve substantially but still have 
comparatively higher mortality. Thinking about 
alterations in the number of deaths or annual rates of 
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change in mortality is useful for understanding how a 
country’s health performance might relate to adjustments 
in policy. Most published work on country performance 
focuses on estimates for mortality levels, but some 
studies are beginning to emerge in which rates of change 
are investigated.5–13 To the extent that rates of change are 
responsive to the introduction of health policies (eg, a 
new immunisation programme), rates of decline in 
mortality oﬀ er a dependent variable to understand the 
eﬀ ect on performance of social and system determinants. 
Nevertheless, rates of change—like any one-dimensional 
metric—still present weaknesses. Notably, large declines 
from high levels of mortality will still lead to an 
unacceptably large number of deaths. Therefore, rates of 
change complement rather than replace the important 
information conveyed by estimates of mortality levels.
The need to measure progress in health has been 
especially apparent in relation to assessing whether 
countries are on track to achieve the Millennium 
Development Goals.10–13 Measuring progress will also be 
crucial to ascertain whether countries can achieve the 
next set of post-2015 Sustainable Development Goals, 
which are ready to be adopted by UN member states in 
2015. The Sustainable Development Goals are likely to 
include one health goal with an associated set of targets; 
several proposals are under discussion.14 The Lancet’s 
Commission on Investing in Health proposed the target 
of achieving a “grand convergence in global health” by 
2035, deﬁ ned as cutting infectious, maternal, and child 
deaths to universally low levels (eg, those seen today in 
the best-performing middle-income countries such as 
Chile and Turkey).15 Other targets have been proposed by 
the Global Investment Framework for Women’s and 
Children’s Health,16 UNICEF,17 the Sustainable 
Development Solutions Network,18 and the High-Level 
Panel on the post-2015 development agenda19 (table 1). 
An intergovernmental open working group recently 
published a draft of the Sustainable Development Goals.20 
Over the next year, these will be debated by all UN 
member states and might undergo revision, before 
adoption in September, 2015.
Studying historical rates of change (rates of decline) in 
mortality across countries over recent decades can be 
helpful to test the feasibility of these diﬀ erent proposals, 
many of which include very ambitious targets for child, 
maternal, tuberculosis, and HIV mortality that would 
require high rates of decline from 2015 to 2030 (the 
probable end date for the Sustainable Development 
Goals). Such targets for mortality can be reality-tested by 
looking at whether high rates of decline in mortality have 
ever been achieved by any low-income or middle-income 
country and could be reproduced for the period 2015–30, 
to enable such ambitious mortality goals to be achieved.
Assessment of a country’s health performance with 
respect to changes in rates of decline in mortality is, 
therefore, valuable when studying the eﬀ ects of policy 
and for testing the feasibility of proposed post-2015 
health goals. We aimed to examine the change in the 
annual rate of decline of key mortality indicators for 
109 low-income and middle-income countries over the 
period 1990–2013.
Methods
For our analysis, we selected four indicators that were 
almost always listed among proposals for post-2015 
health targets (table 1): under-5 mortality, maternal 
mortality, tuberculosis mortality, and HIV mortality. For 
this reason, we did not select malaria and diarrhoea 
The Lancet 
Commission on 
Investing in 
Health15
Global Investment 
Framework for 
Women’s and 
Children’s Health16
UNICEF17 Sustainable Development 
Solutions Network18
High-Level Panel of eminent 
persons on the post-2015 
development agenda19
Timeframe 2035 2035 2035 2030 2030
Under-5 mortality (deaths 
per 1000 livebirths)
16
(interim target of 
20 by 2030)
39 in low-income 
countries, 22 in 
low-to-middle-income 
countries
≤20 ≤20 ≤20
Maternal mortality ratio 
(deaths per 100 000 
livebirths)
83
(interim target of 
94 by 2030)
161 in low-income 
countries, 103 in 
low-to-middle-income 
countries
Eliminate all 
preventable 
maternal deaths
≤40 40
Tuberculosis deaths 
(per 100 000 population 
per year)
4 No targets given No targets given Recommends that “countries 
adopt suitably updated MDG 
indicators for HIV/AIDS, 
tuberculosis, and malaria”
“Decrease the burden of disease 
from HIV/AIDS, tuberculosis, 
and malaria” (no numerical 
targets given)
HIV/AIDS deaths 
(per 100 000 population 
per year)
8 No targets given No targets given Recommends that “countries 
adopt suitably updated MDG 
indicators for HIV/AIDS, 
tuberculosis, and malaria”
“Decrease the burden of disease 
from HIV/AIDS, tuberculosis, 
and malaria” (no numerical 
targets given)
MDG=Millennium Development Goal. *The post-2015 Sustainable Development Goals are being drafted by an intergovernmental open working group.20
Table 1: Selected proposals for post-2015 global health targets 
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mortality (incidentally, these indicators are encompassed 
largely within under-5 mortality) or infectious disease 
mortality more generally. In some regions (eg, southern 
Africa), HIV and tuberculosis mortality correlate highly, 
whereas in others (eg, north Africa and the Middle East), 
these infectious diseases are not major causes of death. 
We assessed the rates of decline in the four chosen 
mortality indicators for 109 low-income and middle-
income countries (as deﬁ ned by the World Bank)21 with 
populations greater than 1 million people.22 The appendix 
(p 1) lists the countries included in the analysis.
We estimated rates of decline in under-5 mortality 
(ie, the number of children who die after birth before 
age 5 years) per 1000 livebirths, the maternal mortality 
ratio (ie, the number of pregnant women who die) per 
100 000 livebirths, tuberculosis mortality (ie, the number 
of deaths from tuberculosis) per 100 000 population per 
year, and HIV mortality (ie, the number of HIV-related 
deaths) per 100 000 population per year. Owing to 
availability of data, we used a 1992–2012 time series for 
under-5 mortality23 and tuberculosis mortality,24 a 
1990–2013 time series for the maternal mortality ratio,25 
and a 2000–10 time series for HIV mortality.26 We used 
several time anchor-points for every indicator: 1992, 1997, 
2002, 2007, and 2012 for under-5 mortality and tuber-
culosis mortality; 1990, 1995, 2000, 2005, and 2013 for the 
maternal mortality ratio; and 2000, 2005, and 2010 for 
HIV mortality. Thus, our calculations diﬀ er from 
annualised rates of reduction computed using diﬀ erent 
timeframes. We calculated 95% uncertainty intervals [UIs] 
around estimates. We used R software for all analyses.
We calculated the annual rate of decline from levels of 
every indicator for every 5-year interval from 1990 to 2013 
(ﬁ gure 1A). In total, we have either two or four estimates 
for the annual rate of decline for every country: 1992–97, 
1997–2002, 2002–07, and 2007–12 for under-5 mortality 
and tuberculosis mortality; 1990–95, 1995–2000, 2000–05, 
and 2005–13 for the maternal mortality ratio; and 
2000–05 and 2005–10 for HIV mortality. Note that 
estimates are mostly taken 5 years apart because of 
estimate availability23–26 and for consistency, with the 
exception of the last increment for maternal mortality, 
which is over an 8-year period.
We calculated the annual rate of change in the annual 
rate of decline (either an acceleration or deceleration) for 
every transition from one 5-year interval to the next, from 
1990 to 2013 (ﬁ gure 1B). In total, we have three values for 
the rate of change in the rate of decline for every country 
for under-5 mortality and tuberculosis mortality (1992–97 
to 1997–2002, 1997–2002 to 2002–07, and 2002–07 to 
2007–12); likewise, we have three estimates corresponding 
to three transitions for the maternal mortality ratio 
(1990–95 to 1995–2000, 1995–2000 to 2000–05, and 
2000–05 to 2005–13). For HIV mortality, we have only one 
value (2000–05 to 2005–10). Note that we use the 
rates of decline from two consecutive 5-year intervals 
(eg, 1995–2000 and 2000–05) to estimate a rate of change 
in the rate of decline for the transition between those 
two intervals. When estimates are available, we could 
analyse continuously a country’s rate of decline per year 
and annual rate of change in the rate of decline. Such an 
analysis could point to rapid changes over short periods, 
and whether acceleration or deceleration takes place 
that is worthy of subsequent assessment. However, 
annual estimates are only available for under-5 mortality 
(appendix p 2). Therefore, for the sake of reporting 
consistency, we present ﬁ ndings in 5-year intervals, which 
also enables clear and concise interpretation of results.
For every mortality indicator, we estimated the year by 
which The Lancet’s Commission on Investing in Health 
target15 would be achieved (ﬁ gure 1C). We obtained 
estimates for every country’s latest rates of decline, 
aspirational best-performer rates of decline (ie, the 
90th percentile for all countries of rates of decline), and 
aspirational rates of decline at the regional level 
(ie, 90th percentile for regional rates of decline). The list 
of regions is presented in the appendix (p 1).
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all data in the paper and SV 
and DTJ had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Tables 2 to 5 show the rates of decline in mortality 
indicators and highlight the best and worst country 
performers (top-ﬁ ve and bottom-ﬁ ve rates of decline). For 
under-5 mortality and maternal mortality, the distribution 
of rates of decline among the 109 low-income and middle-
income countries is narrow (appendix p 3) and becomes 
narrower in the most recent period (2007–12 and 2005–13, 
Figure 1: Calculations
(A) L(t) represents the level of a selected indicator—eg under-5 mortality rate—
in a given country at time t. We calculated the annual rate of change of L(t), 
denoted R(t). The denominator 5 corresponds to the 5-year interval in the 
numerator. Although we generally used 5-year time intervals, occasionally it was 
appropriate to use a diﬀ erent interval; we have noted these cases in the report 
and made the appropriate adjustments. (B) Periods of rapid improvements (or 
worsening) of R(t) are also of policy interest. We calculated RCR(t), the rate of 
change in R(t). (C) Given a rate of change, R, in an indicator from its initial level, 
L, we also calculated the number of years, y, it would take to reach a target T—eg, 
a target under-5 mortality rate of 20 per 1000 livebirths.
A Annual rate of change in the level of a selected indicator
B Rate of change in the annual rate of change in the level of
a selected indicator
C Number of years to reach a specific target
[L(t+5)–L(t)]
5L(t)
R(t) =
[R(t+5)–R(t)]
5R(t)
RCR(t) =
 [In(T)–In(L)]
y =
R
See Online for appendix
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respectively); notably, several countries had very high or 
low rates of decline in maternal mortality. For under-5 
mortality, in 2007–12, the mean rate of decline was 4·3% 
per year (95% UI 3·9–4·6); the aspirational rate was 7·1% 
per year (6·8–7·5) with some variation across regions 
(6·4% [5·4–7·4] for Asia east and south, 7·5% [6·9–8·1] 
for sub-Saharan Africa, 5·5% [4·8–6·2] for north Africa 
and the Middle East, 8·3% [7·3–9·2] for eastern Europe 
and central Asia, and 5·0% [4·4–5·6] for Latin America 
and the Caribbean). The top two performers between 
2007 and 2012 were Macedonia and South Africa, with 
rates of 10·3% and 9·7% per year, respectively (table 2). 
Between 1992 and 2002, for under-5 mortality, countries 
with the lowest performance had negative rates of decline 
(ie, mortality increased) and were largely in southern 
Africa. Some countries (eg, Turkey in 1992–2007) 
maintained very high rates of decline in under-5 mortality, 
above 6·0% per year.
For the maternal mortality ratio, in 2005–13, the mean 
rate of decline was 3·3% per year (95% UI 2·5–4·1); the 
aspirational rate was 6·3% per year (5·5–7·1) with some 
variation across regions (7·6% [6·7–8·6] for Asia east 
and south, 6·1% [5·3–6·9] for sub-Saharan Africa, 4·0% 
[3·2–4·8] for north Africa and the Middle East, 9·9% 
[5·6–14·3] for eastern Europe and central Asia, and 3·3% 
[2·5–4·1] for Latin America and the Caribbean). The top 
performers in 2005–13 were Belarus and Bulgaria, with 
rates of 38·1% and 12·9% per year (table 3). In 1990–95, 
four of the ﬁ ve worst performers were in central Asia 
with large negative rates, below –5·0% per year. For 
1990–2005, Cambodia maintained very high rates, above 
6·0% per year.
2007–12 2002–07 1997–2002 1992–97
Country Rate of decline per 
year (95% UI)
Country Rate of decline per 
year (95% UI)
Country Rate of decline per 
year (95% UI)
Country Rate of decline per 
year (95% UI)
Best performers
1 Macedonia 10·3% (10·0 to 10·7) Rwanda 11·7% (11·3 to 12·1) Turkey 8·1% (7·6 to 8·6) Macedonia 10·8% (10·2 to 11·4)
2 South Africa 9·7% (9·4 to 10·1) Cambodia 10·4% (10·0 to 10·8) Belarus 8·1% (7·6 to 8·6) Serbia 9·3% (8·7 to 9·9)
3 Rwanda 8·6% (8·2 to 9·0) Turkey 9·3% (8·9 to 9·7) Peru 7·3% (6·8 to 7·8) Peru 7·0% (6·4 to 7·6)
4 Belarus 8·4% (8·0 to 8·7) China 9·1% (8·7 to 9·5) Egypt 7·3% (6·8 to 7·8) Turkey 6·5% (5·9 to 7·1)
5 Kazakhstan 8·2% (7·9 to 8·6) Liberia 8·3% (7·9 to 8·7) Brazil 7·2% (6·7 to 7·7) Egypt 6·4% (5·8 to 7·0)
Worst performers
1 Malaysia –1·0% (–1·3 to –0·6) Lesotho –0·2% (–0·6 to 0·2) Swaziland –4·2% (–4·7 to –3·7) Botswana –7·3% (–7·9 to –6·7)
2 Costa Rica 1·0% (0·6 to 1·3) Mauritius –0·1% (–0·5 to 0·3) South Africa –4·1% (–4·6 to –3·6) Swaziland –7·0% (–7·6 to –6·4)
3 Vietnam 1·3% (0·9 to 1·6) Somalia 0·3% (–0·1 to 0·7) Botswana –3·4% (–3·9 to –2·9) Rwanda –5·6% (–6·2 to –5·0)
4 Zimbabwe 1·3% (1·0 to 1·7) DRC 0·4% (0·0 to 0·8) Lesotho –3·3% (–3·8 to –2·8) Zimbabwe –4·3% (–4·9 to –3·7)
5 Mauritius 1·4% (1·1 to 1·8) Zimbabwe 0·8% (0·4 to 1·2) Namibia –1·1% (–1·6 to –0·6) Lesotho –3·6% (–4·2 to –3·0)
UI=uncertainty interval. 
Table 2: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of decline of under-5 mortality, 1992–2012 
2005–13 2000–05 1995–2000 1990–95
Country Rate of decline per 
year (95% UI)
Country Rate of decline per 
year (95% UI)
Country Rate of decline per year 
(95% UI)
Country Rate of decline per year 
(95% UI)
Best performers
1 Belarus 38·1% (37·3 to 38·9) Bulgaria 14·6% (14·0 to 15·2) Serbia 21·0% (20·1 to 21·9) Romania 17·2% (16·5 to 17·9)
2 Bulgaria 12·9% (12·1 to 13·7) Romania 11·4% (10·8 to 12·0) Mauritius 17·7% (16·8 to 18·6) Suriname 15·3% (14·6 to 16·0)
3 Macedonia 8·7% (7·9 to 9·6) Cambodia 10·5% (9·9 to 11·1) Hungary 16·% (15·8 to 17·6) Eritrea 10·6% (9·9 to 11·3)
4 Botswana 8·7% (7·9 to 9·6) Rwanda 9·9% (9·3 to 10·5) Cambodia 9·3% (8·4 to 10·2) Honduras 7·4% (6·7 to 8·1)
5 Kazakhstan 8·2% (7·4 to 9·0) Azerbaijan 9·2% (8·6 to 9·8) Moldova 8·3% (7·4 to 9·2) Cambodia 6·7% (6·0 to 7·4)
Worst performers
1 Mauritius –9·2% (–10·0 to –8·4) Hungary –5·2% (–5·8 to –4·6) Suriname –22·5% (–23·4 to –21·6) Tajikistan –11·4% (–12·1 to –10·7)
2 Serbia –8·7% (–9·6 to –7·9) Mauritius –4·5% (–5·1 to –3·9) Colombia –9·5% (–10·4 to –8·6) Sri Lanka –7·4% (–8·1 to –6·7)
3 Cuba –2·2% (–3·0 to –1·4) Serbia –2·7% (–3·3 to –2·1) Bulgaria –5·5% (–6·4 to –4·6) Kyrgyzstan –6·9% (–7·6 to –6·2)
4 Suriname –2·1% (–2·9 to –1·3) Côte d’Ivoire –2·3% (–2·9 to –1·7) Zimbabwe –4·2% (–5·1 to –3·3) Azerbaijan –6·5% (–7·2 to –5·8)
5 Venezuela –2·0% (–2·8 to –1·2) Argentina –2·1% (–2·7 to –1·5) Macedonia –2·9% (–3·8 to –2·0) Georgia –5·9% (–6·6 to –5·2)
UI=uncertainty interval.
Table 3: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of decline of maternal mortality, 1990–2013 
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Contrary to under-5 mortality and the maternal 
mortality ratio, for tuberculosis mortality, the distribution 
of rates of decline is wider and shows little change over 
time (appendix p 3). During 2007–12, the mean rate of 
decline was 4·1% per year (95% UI 2·8–5·4); the 
aspirational rate was 12·8% per year (11·5–14·1) with 
substantial variation across regions (6·9% [5·6–8·2] for 
Asia east and south, 9·4% [7·6–11·2] for sub-Saharan 
Africa, 13·5% [9·2–17·8] for north Africa and the Middle 
East, 21·7% [17·4–26·0] for eastern Europe and central 
Asia, and 9·4% [6·7–12·1] for Latin America and the 
Caribbean). The best country performances in 2007–12 
were in Uzbekistan and Macedonia, with rates of 31·2% 
and 24·6% per year, respectively (table 4). During 1992–
97, three of the ﬁ ve lowest performers were in central 
Asia, with negative rates larger than –10·0% per year. In 
1997–2007, Rwanda maintained very high rates of decline 
of tuberculosis mortality, higher than 15·0% per year.
For HIV mortality, the distribution of rates is rather 
uniform (appendix p 3). During 2005–10, the mean rate 
of decline was 2·2% per year (95% UI 0·1–4·3); the 
aspirational rate was 15·3% per year (13·2–17·4) with 
important variation across regions (12·8% [6·2–19·3] for 
Asia east and south, 16·4% [13·9–18·8] for sub-Saharan 
Africa, 6·9% [0·2–13·7] for north Africa and the Middle 
East, 10·6% [6·3–14·9] for eastern Europe and central 
Asia, and 15·7% [12·3–19·1] for Latin America and the 
Caribbean). Four of the best country performances were 
in sub-Saharan Africa, with rates higher than 17·0% per 
year (table 5).
The rate of change in the rate of decline enables 
identiﬁ cation of rapid transitions in performance over 
time (tables 6 to 9). For example, in sub-Saharan African 
countries (eg, Botswana), accelerated improvements 
have been seen in under-5 mortality from 1997–2002 to 
2002–07 (table 6). Likewise, eastern European and central 
Asian countries (eg, Azerbaijan) have seen accelerated 
improvements in the maternal mortality ratio from 
1990–95 to 1995–2000 (table 7). Some countries have 
constantly accelerated progress towards higher 
performance (eg, Uzbekistan, with tuberculosis mortality 
over the period 1997–2012; table 8). Progress has been 
made in central Asia and eastern Europe with respect to 
declines in HIV mortality over time (table 9).
A country’s performance with respect to the rate of 
change in mortality diﬀ ers greatly from its performance 
with respect to the number of deaths. Examining rates of 
decline versus number of deaths for under-5 mortality 
and the maternal mortality ratio from 1990 to 2013, we 
found little correlation between the two indicators 
(ﬁ gure 2). Speciﬁ cally, for under-5 mortality, the 
correlation was 0·18 for 1992–97, –0·30 for 1997–2002, 
–0·13 for 2002–07, and –0·07 for 2007–12; for maternal 
2007–12 2002–07 1997–2002 1992–97
Country Rate of decline per year 
(95% UI)
Country Rate of decline per year 
(95% UI)
Country Rate of decline per year 
(95% UI)
Country Rate of decline per year 
(95% UI)
Best performers
1 Uzbekistan 31·2% (29·9 to 32·5) Azerbaijan 29·1% (28·1 to 30·1) Mauritius 21·5% (20·4 to 22·6) Costa Rica 17·8% (16·4 to 19·2)
2 Macedonia 24·6% (23·3 to 25·9) Costa Rica 15·7% (14·7 to 16·7) Cuba 17·3% (16·2 to 17·4) Suriname 17·4% (16·0 to 18·8)
3 Kazakhstan 19·8% (18·5 to 21·1) Rwanda 15·7% (14·7 to 16·7) Rwanda 15·0% (13·9 to 16·1) Venezuela 14·4% (13·0 to 15·8)
4 Ecuador 17·3% (16·0 to 18·6) Turkey 13·9% (12·9 to 14·9) Botswana 12·8% (11·7 to 13·9) Mexico 13·4% (12·0 to 14·8)
5 Turkmenistan 16·3% (15·0 to 17·6) Hungary 13·1% (11·1 to 14·1) Hungary 11·1% (10·0 to 12·2) Macedonia 10·8% (9·4 to 12·2)
Worst performers
1 Swaziland –12·3% (–13·6 to –11·0) Zimbabwe –11·5% (–12·5 to –10·5) Namibia –14·6% (–15·7 to –13·5) Kazakhstan –22·8% (–24·2 to –21·4)
2 Lesotho –10·6% (–11·9 to –9·3) Sierra Leone –11·3% (–12·3 to –10·3) South Africa –10·1% (–11·2 to –9·0) Namibia –18·0% (–19·4 to –16·6)
3 Libya –9·6% (–10·9 to –8·3) Mauritius –7·7% (–8·7 to –6·7) Sierra Leone –8·4% (–9·5 to –7·3) Tajikistan –12·3% (–13·7 to –10·9)
4 Suriname –8·5% (–9·8 to –7·2) Mauritania –4·2% (–5·2 to –3·2) Kenya –7·7% (–8·8 to –6·6) Cameroon –11·5% (–12·9 to –10·1)
5 Angola –8·1% (–9·4 to –6·8) Suriname –3·9% (–4·9 to –2·9) Belarus –7·4% (–8·5 to –6·3) Uzbekistan –10·9% (–12·3 to –9·5)
UI=uncertainty interval.
Table 4: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of decline of tuberculosis mortality, 1992–2012
2005–10 2000–05
Country Rate of decline per year 
(95% UI)
Country Rate of decline per year 
(95% UI)
Best performers
1 Namibia 22·8% (20·7 to 24·9) Hungary 18·0% (15·4 to 20·6)
2 Rwanda 22·5% (20·4 to 24·6) Romania 14·3% (11·7 to 16·9)
3 Burkina Faso 17·7% (15·6 to 19·8) Serbia 12·0% (9·4 to 14·6)
4 Botswana 17·2% (15·1 to 19·3) Uganda 10·6% (8·0 to 13·2)
5 Cambodia 17·0% (14·9 to 19·1) Burkina Faso 10·6% (8·0 to 13·2)
Worst performers
1 Mongolia –34·4% (–36·5 to –32·3) Kazakhstan –56·7% (–59·3 to –54·1)
2 Mauritius –24·3% (–26·4 to –22·2) Belarus –51·0% (–53·6 to –48·4)
3 Indonesia –23·2% (–25·3 to –21·1) Kyrgyzstan –46·5% (–49·1 to –43·9)
4 Pakistan –16·7% (–18·8 to –14·6) Indonesia –36·7% (–39·3 to –34·1)
5 Iran –16·4% (–18·5 to –14·3) Mongolia –36·4% (–39·0 to –33·8)
UI=uncertainty interval.
Table 5: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of decline of HIV mortality, 2000–10
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mortality the correlation was 0·01 for 1990–95, 0·01 for 
1995–2000, 0·13 for 2000–05, and 0·08 for 2005–13. 
These ﬁ ndings show that high rates of decline in 
mortality can be achieved even at low levels of mortality. 
For example, Turkey had a relatively low under-5 
mortality of 47 per 1000 livebirths in 2002, which was 
reduced to 32 per 1000 livebirths in 2007, representing a 
high rate of decline (8·1% per year) for 2002–07.
Figure 3 shows the year when The Lancet’s Commission 
on Investing in Health targets could be achieved with the 
latest rates of decline. For under-5 mortality, 37 (34%) of 
109 countries have already achieved the interim 2030 
target of 20 deaths per 1000 livebirths and 72 have not. 
At current rates of mortality decline, only 25 (35%, 
95% UI 35–39) of these 72 countries would achieve the 
target by 2030 and a further 22 (31%, 29–31) would 
achieve it between 2030 and 2050 (ﬁ gure 3A). With an 
aspirational best-performer rate of decline (at the 
90th percentile), 41 (57%, 50–64) of the 72 countries would 
achieve the target by 2030 and all remaining countries 
(31 [43%, 36–50]) would achieve it over the period 2030–50 
(ﬁ gure 3B). With regional aspirational rates, 32 (44%, 
42–61) of the 72 countries would achieve the target by 
2030 and the remaining countries (40 [56%, 39–58]) 
would achieve it between 2030 and 2050 (ﬁ gure 3C).
For the maternal mortality ratio, 46 (42%) of 
109 countries have already achieved The Lancet’s 
Commission on Investing in Health interim 2030 target 
of 94 deaths per 100 000 livebirths and 63 have not. 
At current rates, 13 (21%, 95% UI 17–29) of these 
63 countries would achieve the target by 2030 and 
19 (30%, 24–33) would meet the target over the period 
2002–07 to 2007–12 1997–2002 to 2002–07 1992–97 to 1997–2002
Country Rate of change in the rate of 
decline per year (95% UI)
Country Rate of change in the rate of 
decline per year (95% UI)
Country Rate of change in the rate of 
decline per year (95% UI)
Best performers
1 South Africa 1·6% (1·5 to 1·7) Botswana 2·0% (1·9 to 2·1) Rwanda 2·5% (2·4 to 2·6)
2 Macedonia 1·5% (1·4 to 1·6) Namibia 1·2% (1·1 to 1·3) Belarus 1·8% (1·7 to 1·9)
3 Swaziland 1·2% (1·1 to 1·3) South Africa 1·2% (1·1 to 1·3) Mauritius 1·6% (1·5 to 1·7)
4 Lesotho 0·8% (0·7 to 0·9) Swaziland 1·2% (1·1 to 1·3) Georgia 1·5% (1·4 to 1·6)
5 Bosnia and Herzegovina 0·7% (0·6 to 0·8) Rwanda 0·9% (0·8 to 1·0) Cambodia 1·5% (1·4 to 1·6)
Worst performers
1 Cambodia –0·9% (–1·0 to –0·8) Mauritius –1·4% (–1·5 to –1·3) Macedonia –0·9% (–1·0 to –0·8)
2 Botswana –0·7% (–0·8 to –0·6) Malaysia –0·9% (–1·0 to –0·8) Serbia –0·8% (–0·9 to –0·7)
3 Serbia –0·6% (–0·7 to –0·5) Bosnia and Herzegovina –0·9% (–1·0 to –0·8) South Africa –0·4% (–0·5 to –0·3)
4 Rwanda –0·6% (–0·7 to –0·5) Macedonia –0·6% (–0·7 to –0·5) Philippines –0·3% (–0·4 to –0·2)
5 Malaysia –0·6% (–0·7 to –0·5) Costa Rica –0·5% (–0·6 to –0·4) Namibia –0·2% (–0·3 to –0·1)
UI=uncertainty interval.
Table 6: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of change in the rate of decline for under-ﬁ ve mortality, 1992–2012
2000–05 to 2005–13 1995–2000 to 2000–05 1990–95 to 1995–2000
Country Rate of change in the rate 
of decline per year (95% UI)
Country Rate of change in the rate 
of decline per year (95% UI)
Country Rate of change in the rate 
of decline per year (95% UI)
Best performers
1 Belarus 5·0% (4·9 to 5·1) Suriname 4·8% (4·6 to 5·0) Serbia 4·6% (4·4 to 4·8)
2 Macedonia 1·2% (1·1 to 1·3) Bulgaria 4·0% (3·8 to 4·2) Tajikistan 3·5% (3·3 to 3·7)
3 Namibia 1·1% (1·0 to 1·2) Colombia 3·1% (2·9 to 3·3) Mauritius 3·4% (3·2 to 3·6)
4 Botswana 1·1% (1·0 to 1·2) Belarus 2·1% (1·9 to 2·3) Hungary 3·3% (3·1 to 3·5)
5 Zimbabwe 1·0% (0·9 to 1·1) Afghanistan 1·3% (1·1 to 1·5) Azerbaijan 2·8% (2·6 to 3·0)
Worst performers
1 Romania –1·3% (–1·4 to –1·2) Serbia –4·7% (–4·9 to –4·5) Suriname –7·8% (–8·0 to –7·6)
2 Serbia –1·1% (–1·2 to –1·0) Mauritius –4·4% (–4·6 to –4·2) Colombia –2·7% (–2·9 to –2·5)
3 Mauritius –1·0% (–1·1 to –0·9) Hungary –4·4% (–4·6 to –4·2) Romania –2·2% (–2·4 to –2·0)
4 Mexico –0·5% (–0·6 to –0·4) The Dominican –1·9% (–2·1 to –1·7) Bulgaria –1·5% (–1·7 to –1·3)
5 Moldova –0·5% (–0·6 to –0·4) Bosnia and Herzegovina –1·1% (–1·3 to –0·9) Belarus –1·4% (–1·6 to –1·2)
UI=uncertainty interval.
Table 7: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of change in the rate of decline for maternal mortality, 1990–2013
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2030–50 (ﬁ gure 3D). At the aspirational rate, 24 (38%, 
35–41) would achieve the target by 2030 and 37 (59%, 
54–59) would achieve it between 2030 and 2050 
(ﬁ gure 3E). At regional aspirational rates, 25 of the 
63 countries (40%, 30–46) would achieve the target by 
2030 and 30 (48%, 48–53) would achieve it between 2030 
and 2050 (ﬁ gure 3F). If the target were 40 per 100 000,18,19 
only 11 (13%, 8–14) of 86 countries (among those having 
not yet achieved target) would achieve the target by 2030 
at current rates, with 27 (31%, 29–37) meeting the target 
at aspirational rates.
For tuberculosis mortality, 32 (29%) of 109 countries 
have already achieved The Lancet’s Commission on 
Investing in Health target of four deaths per 100 000 
population per year and 77 have not. At current rates, 
18 (23%, 95% UI 21–34) of these 77 countries would 
achieve the target by 2030 and 20 (26%, 19–26) would 
achieve it between 2030 and 2050 (ﬁ gure 3G). At the 
aspirational rate, 61 (79%, 74–90) countries would achieve 
the target by 2030 and the remaining 16 (21%, 10–26) 
would achieve it between 2030 and 2040 (ﬁ gure 3H). 
At regional aspirational rates, 48 (62%, 52–78) countries 
would achieve the target by 2030 and the remaining 
29 (38%, 22–48) would achieve it between 2030 and 2050 
(ﬁ gure 3I).
For HIV mortality, 47 (43%) of 109 countries have 
already achieved The Lancet’s Commission on Investing 
in Health target of eight deaths per 100 000 population 
per year and 62 have not. At current rates, 28 (45%, 
95% UI 26–50) of these 62 countries would achieve the 
target by 2030 and 11 (18%, 18–29) would achieve it over 
the period 2030–50 (ﬁ gure 3J). At the aspirational rate, 
49 (79%, 66–82) would achieve the target by 2030 and the 
remaining 13 (21%, 18–34) would achieve it over the 
period 2030–40 (ﬁ gure 3K). At regional aspirational rates, 
42 (68%, 52–82) would achieve the target by 2030 and 
16 (26%, 18–32) countries would achieve it over the 
period 2030–40 (ﬁ gure 3L).
Discussion
We studied over the past two decades the historical rates 
of decline of under-5, maternal, tuberculosis, and HIV 
mortality for 109 countries of low and middle income. 
Between 2005 and 2013, the mean rates of decline were 
4·3% (95% UI 3·9–4·6) per year for under-5 mortality, 
3·3% (2·5–4·1) per year for maternal mortality, 4·1% 
(2·8–5·4) per year for tuberculosis mortality, and 2·2% 
(0·1–4·3) per year for HIV mortality. Best-performer 
rates of decline per year were 7·1% (6·8–7·5), 6·3% 
(5·5–7·1), 12·8% (11·5–14·1), and 15·3% (13·2–17·4), 
respectively, with substantial variation across countries 
2002–07 to 2007–12 1997–2002 to 2002–07 1992–97 to 1997–2002
Country Rate of change in the rate of 
decline per year (95% UI)
Country Rate of change in the rate of 
decline per year (95% UI)
Country Rate of change in the rate of 
decline per year (95% UI)
Best performers
1 Uzbekistan 3·9% (3·6 to 4·2) Azerbaijan 5·0% (4·7 to 5·3) Kazakhstan 6·2% (5·9 to 6·5)
2 Macedonia 3·7% (3·4 to 4·0) Namibia 4·8% (4·5 to 5·1) Mauritius 4·9% (4·6 to 5·2)
3 Kazakhstan 2·4% (2·1 to 2·7) Uzbekistan 3·4% (3·1 to 3·7) Cuba 4·2% (3·9 to 4·5)
4 Ukraine 2·3% (2·0 to 2·6) Kyrgyzstan 3·1% (2·8 to 3·4) Rwanda 4·2% (3·9 to 4·5)
5 Zimbabwe 2·2% (1·9 to 2·5) Thailand 2·7% (2·4 to 3·0) Bulgaria 3·9% (3·6 to 4·2)
Worst performers
1 Azerbaijan –5·8% (–6·1 to –5·5) Mauritius –5·8% (–6·1 to –5·5) Suriname –3·8% (–4·1 to –3·5)
2 Lesotho –3·7% (–4·0 to –3·4) Lebanon –2·3% (–2·6 to –2·0) Kenya –3·2% (–3·5 to –2·9)
3 Cuba –3·1% (–3·4 to –2·8) Cuba –2·0% (–2·3 to –1·7) South Africa –3·2% )–3·5 to –2·9)
4 Georgia –3·1% (–3·4 to –2·8) Zimbabwe –1·8% (–2·1 to –1·5) Costa Rica –2·6% (–2·9 to –2·3)
5 Costa Rica –3·0% (–3·3 to –2·7) Botswana –1·7% (–2·0 to –1·4) Sierra Leone –2·1% (–2·4 to –1·8)
UI=uncertainty interval.
Table 8: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of change in the rate of decline for tuberculosis mortality, 1992–2012
2000–05 to 2005–10
Country Rate of change in the rate of 
decline per year (95% UI)
Best performers
1 Kazakhstan 8·4% (8·0 to 8·8)
2 Belarus 7·0% (6·6 to 7·4)
3 Turkey 6·6% (6·2 to 7·0)
4 Kyrgyzstan 6·5% (6·1 to 6·9)
5 Namibia 6·1% (5·7 to 6·5)
Worst performers
1 Hungary –5·7% (–6·1 to –5·3)
2 Tunisia –4·9% (–5·3 to –4·5)
3 Serbia –4·0% (–4·4 to –3·6)
4 Mauritius –3·0% (–3·4 to –2·6)
5 Morocco –1·6% (–2·0 to –1·2)
UI=uncertainty interval.
Table 9: Top-ﬁ ve and bottom-ﬁ ve country performers in rate of change 
in the rate of decline for HIV mortality, 2000–10
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and regions. During the period 1990–2013, we also 
identiﬁ ed countries with the best and worst performances 
and regions in which rapid changes had taken place 
towards higher or lower performance. Our two aims in 
looking at trends in the rates of decline were to provide a 
dependent variable to assist in identifying potential 
health policy determinants of performance and to ﬁ nd an 
approach to testing the feasibility of proposed post-2015 
health goals.
We aimed to identify speciﬁ c countries and periods 
with good and bad performances in rates of decline of 
mortality indicators, for which further assessment would 
be valuable. Analysing all potential determinants of the 
rates of decline—including contextual factors, speciﬁ c 
circumstances, and system and policy elements—could 
provide useful lessons for improvement of population 
health in the future. Importantly, a country’s health 
performance could be classiﬁ ed by how much the rate of 
decline of a selected outcome (eg, under-5 mortality) is 
better or worse than what would be expected with selected 
contextual attributes (eg, income, education). In a 
subsequent analysis, speciﬁ c variables could be analysed 
(eg, health expenditure, foreign aid) that might isolate the 
remaining determinants of country performance.
Analysis of rates of change in health is useful because 
rapid alterations in rates of decline—whether 
accelerations or decelerations—can point to a potential 
eﬀ ect of policy changes and provide a mechanism to 
better understand what constitutes good policy. We noted 
almost no correlation between numbers of deaths and 
rates of decline in mortality indicators (ﬁ gure 2), which 
suggests that rates of change augment the information 
conveyed by mortality estimates but cannot replace the 
important part played by examination of numbers of 
deaths, particularly in terms of capturing the underlying 
intensity of country-level mortality.
Rates of decline in child mortality indicate the severe 
eﬀ ect that the HIV/AIDS epidemic had in southern 
Africa. In this region, very large increases were recorded 
in child mortality over the period 1997–2002, but 
numbers of deaths fell rapidly from 2002 to 2007, 
probably because of rollout of antiretroviral therapy 
(ART) for the prevention of mother-to-child transmission 
of HIV.27,28 Likewise, rates of decline in maternal and 
tuberculosis mortality deteriorated during 1990–97 in 
many central Asian countries after the collapse of the 
Soviet Union in 1991, and rates of decline in child 
mortality dropped abruptly in Rwanda from 1992 to 1997, 
probably because of the genocide in 1994. A few countries 
have sustained high rates of decline—eg, child mortality 
in Turkey from 1992 to 2007, maternal mortality in 
Cambodia over the period 1990–2005, tuberculosis 
mortality in Rwanda between 1997 and 2007, and HIV 
mortality in Burkina Faso during 2000–10. Did unusual 
circumstances or speciﬁ c policies account for these 
changes in mortality? Indeed, subsequent assessments 
could control for contextual determinants (eg, income) 
and exceptional events (eg, natural disasters and political 
instabilities) and try to identify the contributions of 
speciﬁ c policies implemented. For instance, Turkey’s 
high rates of decline in child mortality coincide with 
substantial economic growth, political stability, and 
introduction of the Health Transformation Program, 
which rapidly expanded access to health-care services.29 
Cambodia’s progress in maternal mortality can probably 
be attributed to socioeconomic improvements and better 
primary education and to speciﬁ c policies leading to 
increases in skilled birth attendance.30 For Burkina Faso, 
Figure 2: Correlation of rate of decline in mortality with number of deaths
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Figure 3: Year by which The Lancet’s Commission on Investing in Health targets could be achieved
Grey line represents 2012 for under-5 and tuberculosis mortality, 2013 for maternal mortality, and 2010 for HIV mortality. Dotted lines are at 2030 and 2050. Regions and country codes are deﬁ ned in 
the appendix (p 1).
2020
2040
2060
2080
2100
2120
2020
2040
2060
2080
2100
2120
2020
2040
2060
2080
2100
2120
Ye
ar
 b
y w
hi
ch
 2
0 
pe
r 1
00
0 
ta
rg
et
 is
 a
ch
ie
ve
d
A Under-5 mortality at current rates of decline
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
2010
2020
2030
2040
2050
2060
Ye
ar
 b
y w
hi
ch
 2
0 
pe
r 1
00
0 
ta
rg
et
 is
 a
ch
ie
ve
d
B Under-5 mortality at best-performer rates of decline
Ye
ar
 b
y w
hi
ch
 2
0 
pe
r 1
00
0 
ta
rg
et
 is
 a
ch
ie
ve
d
C Under-5 mortality at regional best-performer 
rates of decline
2020
2040
2060
2080
2100
2140
2120
Ye
ar
 b
y w
hi
ch
 9
4 
pe
r 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
D Maternal mortality at current rates of decline
Ye
ar
 b
y w
hi
ch
 9
4 
pe
r 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
E Maternal mortality at best-performer rates of decline
Ye
ar
 b
y w
hi
ch
 9
4 
pe
r 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
F Maternal mortality at regional best-performer 
rates of decline
Ye
ar
 b
y w
hi
ch
 4
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
G Tuberculosis mortality at current rates of decline
Ye
ar
 b
y w
hi
ch
 4
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
H Tuberculosis mortality at best-performer rates of decline
Ye
ar
 b
y w
hi
ch
 4
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
I Tuberculosis mortality at regional best-performer 
rates of decline
Ye
ar
 b
y w
hi
ch
 8
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
J HIV mortality at current rates of decline
Ye
ar
 b
y w
hi
ch
 8
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
K HIV mortality at best-performer rates of decline
Ye
ar
 b
y w
hi
ch
 8
 p
er
 1
00
 0
00
 ta
rg
et
 is
 a
ch
ie
ve
d
L HIV mortality at regional best-performer 
rates of decline
AFG
BGD
CHN
IND LAO
MMR
NPL
PNG
LKA
THA
VNM
BEN
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
KEN
LBR
MDG
MLI
MRT
MUS
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
TZA
ZMB
ZWE
BRA
CRI
CUB
DOM
ECU
SLV
GTM
HTI
HND
JAM
MEX
NIC
PRY
PER
VEN
ALB
ARM
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TKM UKREGY
JOR
LBY
MAR
SYR
TUR
YEM
AFG
BGD
CHN
IND
LAO
MMR
NPL
PNG
LKA
THA
VNM
BEN
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
KEN
LBR
MDG
MLI
MRT
MUS
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
TZA
ZMB
ZWE
BRA
CRI
CUB
DOM
ECU
SLV
GTM
HTI
HND
JAM
MEX
NIC
PRY
PER
VEN
ALB
ARM
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TKM
UKR
EGY
JOR
LBY
MAR
SYR
TUR
YEM
AFG
BGD
CHN
IND
LAO
MMR
NPL
PNG
LKA
THA
VNM
BEN
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
KEN
LBR
MDG
MLI
MRT
MUS
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
TZA
ZMBZWE
BRA
CRI
CUB
DOM
ECU
SLV
GTM
HTI
HND
JAM
MEX
NIC
PRY
PER
VEN
ALB
ARM
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TKM
UKR
EGY
JOR
LBY
MAR
SYR
TUR
YEM
AFG
BGD
CHN
LAO
MMR
NPL
PNG
VNM
BEN
BFA
BDI
CAF
TCD
ETH
GAB
GMB
GIN
KEN
LBR
MDG
MLI
MRT
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
ZMB
ZWE
BRA
CRI
ECU SLV
GTM
HTI
HND
JAM
MEX
NIC
PRY
PER
ALB
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TKM
EGY
LBY
MAR
SYR
TUR
YEM
AFG
BGD
CHN
LAO
MMR
NPL
PNG
LKA
VNM
BEN BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
KEN
LBR
MDG
MLI
MRT
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
ZMB
ZWE
BRA
CRI
ECU
SLV
GTM
HTIHND
JAM
MEX
NIC
PRY
PER
ALB
AZE
BLR
GEO
KAZ
MDAROU
SRB
TKM
UZB
EGY
LBY
MAR
SYR
TUR
YEM
AFG
BGD
CHN
LAO
MMR
NPL
PNG
LKA
VNM
BEN BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
KEN
LBR
MDG
MLI
MRT
NAM
NER
NGA
RWA
SEN
SOM
SDN
SWZ
ZMB
ZWE
BRA
CRI
ECU
SLV
GTM
HTI
HND
JAM
MEX
NIC
PRY
PER
ALB
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TKM
UZB
EGY
LBY
MAR
SYR
TUR
YEM
MMR
NPL
PAK
PNG
PHL
THA
VNM BWA
BFA
BDI
CMR
CAF
ETH
GAB GIN
KEN
MDG
MLI
MRT
MUS
MOZ
NAM
NGA
SWZ
UGA
ARG
BRA
CRI
ECU
SLV
HTI
HND
PAN
VEN
AZE
BLR
BIH
KAZ
ROU
TJK
TKM
EGY
IRQ
JOR
LBY
MAR
SYR
AFG
BGD
CHN LAO
MMR
NPL
PAK
PNG
PHL
THA
VNM
BEN
BWA
BFA
BDI
CMR
CAF
TCD
CIV
ERI
ETH
GAB
GMB
GIN
KEN
LSO
LBR
MDG
MLI
MRT
MUS
MOZ
NAM
NER
NGA
RWA
SEN
SOM SDN
SWZ
UGA
ZMB
ZWE
ARG
BRA
CRI
ECU
SLV
HTI
HND
JAM
MEX
PAN
PRY
VEN
ALB
ARM
AZE
BLR
BIH
GEO
KAZ
MKD
MDA
ROU
SRB
TJK
TKM
EGY
IRQ
JOR
LBN
LBYMAR
SYR
TUR
YEM
AFG
BGD
CHN
LAO
MMR
NPL
PAK
PNG
PHL
THA
VNM
BEN
BWA
BFA
BDI
CMR
CAF
TCD
CIV
ERI
ETH
GAB
GMB
GIN
KEN
LSO
LBR
MDG
MLI
MRT
MUS
MOZ
NAM
NER
NGA
RWA
SEN
SOM SDN
SWZ
UGA
ZMB
ZWE
ARG
BRA
CRI
ECU
SLV
HTI
HND
JAM
MEX
PAN
PRY
VEN
ALB
ARM
AZE
BLR
BIH
GEO
KAZ
MKD
MDA
ROU
SRB
TJK
TKM
EGY
IRQ
JOR
LBN
LBYMAR
SYR
TUR
YEM
BGD
CHN
IDN
LAO
MMR
LKA
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GIN
LBR
MLI
NAM
RWASEN
SLE
SOM
SDN
SWZ
ZMB
ZWE
BRA
CRI
CUB
ECU
SLV
GTM
HND
JAM
MEX
PRY
VEN
ALB
AZE
BLR
KAZ
MDA
ROU
TJK
TKM
UKR
EGY
MAR
SYR
TUR
YEM
BGD
CHN
IDN
LAO
MMR
NPL
PAK
LKA
AGO
BWA
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
LBR
MDG
MLI
MOZ
NAM
NER
RWA
SEN
SLE
SOM
SDN
SWZ
UGA
ZMB
ZWE
BRA
CRI
CUB
ECU
SLV
GTM
HND
JAM
MEX
PRY
VEN
ALB
AZE
BLR
GEO
KAZ
MDA
ROU
SRB
TJK
TKM
UKR
EGY
MAR
SYR
TUR
YEM
BGD
CHN
IDN
LAO
MMR
NPL
PAK
LKA
AGO
BWA
BFA
BDI
CMR
CAF
TCD
ETH
GAB
GMB
GHA
GIN
LBR
MDG
MLI
MOZ
NAM
NER
RWA
SEN
SLE
SOM
SDN
SWZ
UGA
ZMB
ZWE
BRA
CRI
CUB
ECU
SLV
GTM
HND
JAM
MEX
PRY
VEN
ALB
AZE
BLR
GEO
KAZ MDA
ROUSRB
TJK
TKM
UKR
EGY
MAR
SYR
TUR
Asia, east and south
Sub-Saharan Africa
Latin America and the Caribbean
Eastern Europe and central Asia
North Africa and Middle East
Articles
e707 www.thelancet.com/lancetgh   Vol 2   December 2014
a rapid expansion of ART (up to 70% in 2012) led to 
striking improvements in HIV mortality.31
We used the rates of decline in mortality to test the 
feasibility of achieving post-2015 goals, with a particular 
focus on the 2030 targets proposed by The Lancet’s 
Commission on Investing in Health. Because post-2015 
goals present ambitious targets for levels of mortality, they 
would need high (aspirational) rates of mortality decline 
from 2015 to 2030. Hence, we used historical rates of 
decline—including best-performer aspirational rates—to 
identify how many countries would achieve these 
ambitious targets if they were to have these similar rates 
of decline over the period 2015–30. If all countries of low 
and middle income were able to achieve best-performer 
aspirational rates of decline in mortality, most would meet 
the targets for tuberculosis and HIV mortality, about half 
would reach the child mortality target, but fewer than half 
would meet the maternal mortality target.
Similar methods can be used to assess the feasibility of 
other possible Sustainable Development Goal targets. 
Norheim and colleagues32 suggested (in addition to 
speciﬁ c subtargets for under-5 mortality, etc) an 
overarching goal to reduce premature (younger than 
70 years) deaths by 40% in 2030 from what they would 
have been in 2010. Figure 4 shows mortality estimates 
for 2030 that were predicted from the distribution of 
changes in rates of decline in premature deaths across 
countries in 2000–10. To the right of the cutoﬀ , 
21 countries had rates of decline suﬃ  ciently rapid that, if 
continued for two decades to 2030, they would meet the 
40% reduction target.
Periods of high rates of decline in mortality, such as 
those seen among best-performers (tables 2 to 5), can be 
diﬃ  cult to sustain. Indeed, we noted a strong negative 
correlation between the rate of decline and the rate of 
change in the rate of decline (eg, –0·60 and –0·80 for 
under-5 mortality and the maternal mortality ratio, 
respectively). Thus, when high rates of decline were 
recorded, negative rates of change in rates of decline (ie, 
decelerations) were sometimes recorded, leading to a 
reduction from higher to lower rates of decline.
Even if some countries can emulate the best 
performances recorded in recent years with respect to 
rates of decline in infectious, child, and maternal mortality, 
our ﬁ ndings suggest they will not meet proposed 2030 
global health targets. These countries will need to achieve 
highly accelerated rates of decline in mortality. How can 
such acceleration be achieved? A ﬁ rst approach would be 
aggressive and accelerated scale-up of evidence-based 
medicines, vaccines, diagnostics, and other health 
strategies to very high coverage levels; a second would be 
to scale-up investments in discovery, development, and 
delivery of new health technologies. Both these approaches 
were captured in The Lancet’s Commission on Investing 
in Health modelling method but were not included 
in our best-performer modelling. Two methodological 
diﬀ e rences could account for why some countries in our 
model did not reach 2030 targets. First, the Commission’s 
approach began by modelling the scale-up of a wide range 
of evidence-based interventions (eg, ART and skilled birth 
attendance) to very high (typically 90%) coverage levels by 
2030. The model assumes that very aggressive intervention 
scale-up will be possible across all countries of low and 
middle income based on actual rates of scale-up in recent 
years in several countries. Second, the Commission’s 
model also assumes that discovery and development of 
new medicines, vaccines, and diagnostics will lead to an 
additional 2% per year decline in under-5, maternal, HIV, 
and tuberculosis mortality, an assumption based on 
empirical research on the eﬀ ect of research and 
development on mortality declines.33 Taken together, these 
diﬀ erences indicate that the Commission’s modelling is 
more optimistic than is ours about what can be achieved 
by 2030.
Our analysis has four key limitations. First, for some 
countries with poor data, the mortality estimates we 
used23–26 were predicted largely from past trends. Many 
countries, particularly those with high mortality, do not 
have vital registration so mortality estimates are not 
always reliable. In view of the large number of countries 
and distinct mortality indicators analysed, some ﬁ ndings 
might also be attributable to poor quality of data. 
We used UNICEF and WHO mortality estimates23–26 to 
draw general lessons, but our ﬁ ndings could be further 
strengthened by incorporation of additional sources 
(panel).12,13,34–36
Second, 5-year intervals were chosen because of the 
availability of estimates23–26 and for conciseness, but this 
Figure 4: Distribution of predicted change in premature deaths by 2030 
among countries of low and middle income
Age-standardised death rates from 2000 and 2010 (which were generally lower 
than in 2000) were applied to the 2030 population (UNPD medium-variant 
projection), yielding two numbers for deaths in 2030. The change per decade (%) 
compares these values. To achieve a 40% reduction in premature (younger than 
70 years) deaths by 2030, a change of 23% per decade (dotted line) will be needed.
Change per decade (%)
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period might oversmooth changes of interest. If available, 
alternative intervals could be analysed, which would aﬀ ect 
country performance rankings. Despite noise, annual 
outcomes could be looked at to isolate inﬂ ection points 
that capture times when countries make performance 
transitions (appendix p 2). This approach would also help 
identify seasonal variations and cyclical patterns that 
longer intervals (eg, every 5 years) might be unable to 
ﬂ ag. The choice of interval represents a trade-oﬀ  between 
accuracy and the relevance of ﬁ ndings to policy.
A third limitation is that our analysis includes 
four mortality indicators that correlate highly across 
countries for a speciﬁ c period and over time for a 
particular country. For example, correlation over the 
entire period was 0·90 between the maternal mortality 
ratio and under-5 mortality, 0·58 for under-5 and 
tuberculosis mortality, and 0·59 for the maternal 
mortality ratio and tuberculosis mortality. Correlation 
might aﬀ ect the feasibility of the post-2015 targets, 
because countries achieving poor results for one indicator 
might be faring badly in another. Nevertheless, we noted 
little correlation between the rates of decline of the 
four indicators: 0·35 between under-5 mortality and the 
maternal mortality ratio, 0·15 for under-5 and tuberculosis 
mortality, and –0·01 for the maternal mortality ratio and 
tuberculosis mortality, which suggests that successful 
improvements towards targets might not be aﬀ ected.
The ﬁ nal limitation is that other modelling techniques 
could be used to forecast the rates of decline in mortality 
and to ascertain whether countries would achieve targets 
by 2030. For instance, speciﬁ c explanatory variables 
related to declines in mortality could be used, and 
regression models could be ﬁ tted to mortality time series 
to make future predictions. However, we opted for a 
simple and intuitive approach based on historical rates of 
decline in mortality, which are easily communicable to 
policymakers.
In conclusion, if recent aspirational best-performer 
rates of decline could be achieved in countries of low and 
middle income, most would meet The Lancet’s 
Commission on Investing in Health targets for 2030 for 
tuberculosis and HIV mortality, about half would reach 
the child mortality target, and fewer than half would 
meet the maternal mortality target. Aggressive scale-up 
of evidence-based interventions together with discovery 
and development of new health strategies will be needed 
to achieve further acceleration of declines in mortality. 
Rates of decline provide a necessary starting point for 
assessment of the importance of health policy 
determinants and for deﬁ ning realistic targets for the 
Sustainable Development Goals.
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